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Surface engineering of porous silicon to optimise
therapeutic antibody loading and release†
Steven J. P. McInnes,a Chris T. Turner,b Sameer A. Al-Bataineh,b
Marta J. I. Airaghi Leccardi,a Yazad Irani,c Keryn A. Williams,c Allison J. Cowinb and
Nicolas H. Voelcker*a
The proinflammatory cytokine, tumor necrosis factor-a (TNF-a), is elevated in several diseases such
as uveitis, rheumatoid arthritis and non-healing chronic wounds. Adding Infliximab, a chimeric IgG1
monoclonal antibody raised against TNF-a, to chronic wound fluid can neutralise human TNF-a, thereby
providing a potential therapeutic option for chronic wound healing. However, to avoid the need for
repeated application in a clinical setting, and to protect the therapeutic antibody from the hostile
environment of the wound, suitable delivery vehicles are required. Porous silicon (pSi) is a biodegradable
high surface area material commonly employed for drug delivery applications. In this study, the use of
pSi microparticles (pSi MPs) for the controlled release of Infliximab to disease environments, such as
chronic wounds, is demonstrated. Surface chemistry and pore parameters for Infliximab loading are first
optimised in pSi films and loading conditions are transferred to pSi MPs. Loading regimens exceeding
60 mg of Infliximab per mg of pSi are achieved. Infliximab is released with zero-order release kinetics
over the course of 8 days. Critically, the released antibody remains functional and is able to sequester
TNF-a over a weeklong timeframe; suitable for a clinical application in chronic wound therapy.
Introduction
Protein therapeutics are becoming more and more prevalent in
the treatment of a variety of diseases and medical conditions.1,2
However, as proteins are relatively unstable and readily degraded,
there is a need to develop alternative eﬀective delivery systems.3
These delivery systems need to protect the protein from degrada-
tion by proteases and hydrolytic conditions whilst also being
completely biodegradable naturally in the body after implantation
or injection.3
Porous silicon (pSi) is a biomaterial that is now under
intense focus as it has several unique properties that make it
very attractive for use in a wide variety of in vivo and ex vivo
applications.4,5 Bulk crystalline silicon is converted into the
high surface area and biocompatible pSi by means of anodisa-
tion in hydrofluoric acid (HF) solution. A broad range of porous
structures can be generated by altering the wafer resistivity, HF
concentrations and the applied current densities. The pore size
can be tuned in diameter from a few nanometers to a few
microns achieving surface areas of up to 800 m2 g1.3,6 pSi
degradation is tunable, from days to months,3,7,8 depending on
the pore size and chemistry and produces non-toxic silicic
acid.6,9–11 pSi has demonstrated in vivo biocompatibility in
the subconjuctival space of rats12 and when injected into the
vitreous of rabbit eyes.13 Bimbo et al. have also demonstrated
the biodistribution of pSi nanoparticles (NPs) administered
via oral, subcutaneous and intravenous administration and
shown that the pSi NPs do not induce toxicity or inflammatory
responses whilst displaying excellent in vivo stability in rats.14
Ex vivo applications include optical biosensors that capitalise
on the unique optical and photonic properties of the material
and have been exploited in the fields of immunology,15 cancer
diagnostics,16 chronic wound healing17,18 and infectious
diseases.19 The ability of pSi to store and release various pay-
loads of small molecular, oligonucleotide or even protein
therapeutics has also been demonstrated.20–22
Immediately after fabrication, pSi is hydride-terminated and
degrades within minutes when immersed in neutral aqueous
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medium. However, the surface chemistry of pSi can be easily
modified by techniques such as oxidation, silanisation, hydro-
silylation, hydrocarbonisation and electrografting in order to
impart varying degrees of stability to the material in addition to
introducing functional groups.23–26 Certain surface modifica-
tions including thermal hydrocarbonisation render pSi stable
even in harsh conditions such as exposure to strong aqueous
bases.27 The ability of pSi to degrade into non-toxic silicic acid
upon exposure to physiological conditions is a key advantage
over other biomaterials.28 The choice of surface chemistry also
plays an important role in the ability to load different drugs
and must therefore be chosen carefully.20,29 A range of in vivo
and in vitro studies have demonstrated the biocompatibility
of surface-modified pSi.11,28,30,31 We recently demonstrated
composite pSi and poly(e-caprolactone) (PCL) membranes can
be implanted into the subconjunctival space of rats.32 These
membranes did not erode or cause inflammatory responses in
the tissue surrounding the implant and there was also no
evidence of vascularisation.
pSi is being exploited for applications in drug delivery
including in several preclinical and clinical settings.12,33,34
A particularly suitable format of pSi for drug delivery are pSi
microparticles (pSi MPs) that are fabricated to the desired size
from ‘‘free-standing’’ membranes of pSi by sonication35–38 or
other mechanical forces, such as ball milling.39 Given their
fabrication from pSi films, those MPs have a characteristic
plate shape. The Sailor laboratory has developed pSi MPs
suitable for injection into the vitreous humor,13 has shown
intravitreal drug release for up to 6 months33,40 and the ability
to tune drug release by varying the pore size41 or polymer
encapsulation of the pSi MPs.42 They have also extensively
studied how the pSi dissolution by-products are cleared from
the vitreous humor after injection of pSi MPs.43
Receptor proteins, including antibodies, can be both electro-
statically bound or conjugated to pSi MPs or NPs for targeting44,45
or biosensing15,46 applications employing various chemistries
such as thermal oxidation,46 amino-terminated silanes,47 or using
semicarbazide,44 EDC/NHS48 or click49 chemistries. But very few
examples exist in the literature describing the release of thera-
peutic proteins from pSi. One early example was performed by
Foraker et al.50 who used micromachined pSi particles to deliver
insulin across intestinal Caco-2 cell monolayers. They found that
the flux of insulin from the pSi particles was nearly 10 times
higher than from insulin in solution and 100 times higher when
permeation-enhancing chemicals were omitted in that solution.
Likewise, Wu and Sailor have used a polymeric chitosan-based
hydrogel to cap the top of pSi films and demonstrate controlled
release of insulin from the underlying porous structure in a
switchable pH dependent fashion.51 In 2007, Prestidge et al.52
used pSi powders to load and release papain, a model hydrophilic
protein. It was observed that the powders, anodised and stain-
etched, used in this study varied in surface chemistry, which
subsequently aﬀected the loading and burst release of the enzyme
from the material. More recently, Andrew et al.21 loaded a
thermally oxidised pSi film with Avastin, a monoclonal antibody,
and demonstrated a sustained release of 98% of active antibody
after 1 month, but the authors did not translate this system to a
fully degradable pSi MP format. The retention of the active form
of the protein released from pSi MPs and NPs has also been
demonstrated by other groups53 emphasising the careful choice
of surface chemistry to minimise possible denaturation.54
Infliximab is a chimeric IgG1 monoclonal antibody raised
against tumor necrosis factor-a (TNF-a). This antibody is clini-
cally approved to treat Crohn’s disease55 and rheumatoid
arthritis.56 Infliximab functions by neutralising the function
of TNF-a. Infliximab has also been studied for the treatment of
psoriasis,57,58 ulcerative colitis,59,60 pyoderma gangrenosum,61
chronic venous ulcers62 and uveitis.63 Non-healing chronic
wounds including venous leg ulcers aﬀect 1–2% of the popula-
tion in developed countries and place a significant burden on
the community, estimated to cost $15 billion dollars per year
worldwide.64 TNF-a has been demonstrated to be elevated in
venous leg ulcers and Infliximab has proven successful in
reducing TNF-a levels.62 Uveitis, also an inflammatory condition,
occurs in the uveal tract and is responsible for 10% of visual loss
in developing nations.65 Typical treatment is with topical and
oral glucocorticosteroids and often patients receiving this treat-
ment display significant side effects and insufficient therapeutic
responses. Topically applied Infliximab has performed well in
the reduction of scarring on the ocular surface in a mouse ocular
surface scarring model.63
However, side eﬀects of the systemic delivery of high-dose
anti-TNF-a agents, including Infliximab and Etanercept, include
drug-induced lupus66 and treatment must be discontinued
in these cases. Hence, the development of better delivery systems
for anti-TNF-a, particularly those that can sustain low-dose
release over a prolonged timespan, could prove beneficial for
patient well-being and continual treatment. Indeed, previous
studies have shown that the topical application of 10 mg mL1
Infliximab as a solution or gel and covered with an adhesive
bandage could reduce ulcer healing time to 8 weeks in
approximately 30% of cases, while the other 70% of ulcers
treated had healed significantly, showing a 75% reduction in
size.67 Similarly, the one oﬀ implantation or injection of a
sustained drug delivery for Infliximab to the cornea and
anterior segment may prove a safe and eﬀective way to reduce
the number of treatments required for anterior uveitis, hence
improving patient care.
The current study aims to demonstrate the versatility of pSi
as a reservoir for Infliximab delivery in both in vivo and ex vivo
applications. pSi films with diﬀerent pore size were prepared by
electrochemical etching and thermally oxidised at a range of
temperatures. The optimal etching conditions found for the
films were then transferred to pSi MPs, which are fully degrad-
able and, in contrast to pSi films, can be used for implantation
or injection. pSi MPs were immersed in the antibody solution,
allowing the positively charged protein to penetrate into the
pores by electrostatic attraction with the negatively charged
surface. Antibody loading was quantified using interferometric
reflectance spectroscopy and UV-Vis spectroscopy. Infliximab
released from pSi MPs remained active and was able to neutralise
TNF-a (Scheme 1), potentially providing an improved therapeutic
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delivery system for the treatment of chronic wounds and ocular
conditions such as uveitis.
Experimental details
Chemicals
Hydrofluoric acid (HF) 48% (Merck), dichloromethane (CH2Cl2,
Labserv, analytical grade, 99.5%), methanol (Merck, analytical
grade, 99.5%), acetone (Ajax, analytical grade, 99.5%), and
ethanol (Ajax, absolute, 100%) were used without further
purification. N,N-Dimethylformamide (DMF, EMD Chemicals,
Belgium) was purified via standard laboratory protocols including
drying over MgSO4 followed by distillation at reduced pressure.
68
Milli-Q water was obtained from an Advantage A10 water purifica-
tion system provided by Merck Millipore (water resistivity of
18.2 MO cm at 25 1C, TOCo 5 ppb). Phosphate buﬀered saline
(PBS) solution was prepared by dissolving one PBS tablet
(Sigma) in 200 mL of MilliQ water, giving a pH of 7.4.
Infliximab (Remicades) powder was purchased from Janssen,
Australia. Each vial contains 100 mg of Infliximab, 6.1 mg of
sodium phosphate dibasic dehydrate, 2.2 mg of sodium phos-
phate monobasic monohydrate, 500 mg of sucrose and 0.5 mg of
polysorbate 80. The undiluted Infliximab powder was stored at
4 1C. Before use the Infliximab powder was diluted to 1 mgmL1
with MilliQ water (10 mL).
pSi film preparation
Si wafers (p-type boron doped with a resistivity range of
0.00055–0.001 O cm and a h100i crystal orientation) were cut
in 3–4 cm2 pieces, washed with high purity ethanol (Ajax,
absolute, 100%) and placed into a Teflon cell, between two
electrodes (a platinum mesh as cathode and an aluminum foil
as anode for the back contact of Si). The exposed surface area
was 1.767 cm2 and the distance between the silicon and the Pt
cathode was approximately 1.5 cm. A Keithley 2425 100 W
Source Meter was used for anodisation. Etching current and
time were controlled by a custom written Labview 8.2 computer
program. Polished silicon wafers (CZ process, diameter of
76.2 mm and thickness between 475–525 mm) were provided
by Siltronix. The wafer pieces were etched in a 3 : 1 HF : ethanol
(v/v) solution. One sacrificial etching step was carried out at
200 mA (113 mA cm2) for 15 s and the freshly etched surface
was washed with ethanol before treatment with 1 N sodium
hydroxide for 1 min. The silicon surface was washed again with
MilliQ water and ethanol and dried under nitrogen gas. The
second etching process was performed with etching current
densities ranging from 150 to 233 mA cm2 and etching times
of 15 to 291 s. After etching, washes were performed with
ethanol and dichloromethane and dried with nitrogen gas.
pSi MP preparation
Microparticles were fabricated from p-type Si wafers (boron-
doped, resistivity o 0.001 O cm, h100i) supplied by Virginia
Semiconductors (Fredericksburg, VA, USA). The wafer was
anodised in an 18 cm2 etching cell in 3 : 1 HF : ethanol (v/v)
solution with a current density of 222 mA cm2 for 4 min, and
then electropolished for 30 s at 500 mA cm2. Then, 20 min of
sonication was performed (S30H Elmasonic, 280 W, Elma) to
fracture the pSi membrane into MPs. The pSi MP suspension
was filtered, washed with ethanol and dichloromethane before
drying to completeness.
Gravimetric analysis
The porosity of pSi was determined by weight measurements.
To do this, the wafer is weighed before etching (m1), after
etching (m2) and after the porous layer is dissolved from the
Scheme 1 (A) Crystalline silicon wafer prior to (B) electrochemical anodization to produce a pSi film. The film is then removed from the crystalline
substrate via an electropolishing etch (C). The resulting free-standing pSi film is sonicated to generate pSi microparticles (MPs) which are subsequently
oxidised at 400 1C (D) and then loaded with the therapeutic antibody Infliximab (E). The Infliximab is released from the pSi and neutralizes TNF-a (F).
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bulk Si, with NaOH (m3). These three values can then be used to
calculate the porosity using the following equation:5
Porosity (%) = (m1  m2)/(m1  m3) (1)
Zeta potential
The surface zeta (z)-potential of pSi MPs was determined by
using a disposable zeta potential cell on a Zetasizer Nano ZS
(Malvern Instruments). The analysis was carried out at a
temperature of 25 1C using pSi MPs dispersed in PBS buﬀer
at pHs ranging from 5.5 to 8.5. Zeta potential was acquired
from 50 runs performed in triplicate for each sample.
Thermal oxidation
A Labec horizontal tube furnace (heating rate of 20 1C min1)
was used to thermally oxidise the freshly etched pSi. Samples
being oxidised were situated in the middle of the furnace and
the ends of the tube were closed with ceramic caps. Various
oxidation temperatures (300, 400 and 500 1C) were used. All
thermal oxidations commenced at room temperature and the
furnace was ramped to the desired temperature before remaining
at that constant temperature for 1 h. The pSi samples were
allowed to slowly cool to room temperature inside the furnace.
The oxidised films were cut in two smaller pieces leaving out
the rim of the etched area. The pieces were then washed in
ethanol and dried with nitrogen gas before being loaded with
Infliximab (see loading section below).
Time-of-flight secondary ion mass spectrometry (TOF-SIMS)
ToF-SIMS measurements were performed using a Physical
Electronics Inc. PHI TRIFT V nanoToF instrument (Chanhassen,
MN, USA) equipped with a pulsed liquid metal Au+ primary ion
gun (LMIG), operating at 30 kV. The extractor current of the
ion source was maintained at 3 mA. Positive ion ToF-SIMS
images (200 mm  200 mm) were acquired on the unloaded
and infliximab-loaded oxidised porous silicon macro-particles
using ‘unbunched’ Au1 beam settings to deliver optimised
spatial resolution. Positive ion mass spectra (200 mm  200 mm)
were acquired on the same surfaces using a ‘bunched’ Au1 beam
setting for optimal mass resolution. The acquisition time for both
images and spectra was 5 min each. Mass calibration of the
spectra was done with CH3
+, C2H5
+, and C3H7
+ ions. Experiments
were performed a high vacuum (o108 Torr), in static mode
(i.e. below 1012 ions per cm2) to minimise sample damage.
Infrared spectroscopy
Attenuated total reflectance infrared (ATR-IR) spectra were
obtained using a Bruker Hyperion 1000 IR microscope operating
with a Bruker Vertex 80 IR spectrometer. The IR microscope was
equipped with a liquid nitrogen cooled MCT detector. ATR
spectra were collected over 64 scans, with a resolution of
4 cm1, using a Ge ATR crystal. All spectra were background
corrected with an unetched silicon wafer of the same type.
Spectra of the pSi layers were recorded and analysed using OPUS
version 7.0 software, in the range of 650–4000 cm1. All IR
spectra are presented with absorbance normalised to the Si–O
peak at approximately 1100 cm1.
Scanning electron microscopy (SEM)
SEM was performed on a FEI Quanta 450 FEG environmental
SEM fitted with an SSD detector, and operated at 30 keV with a
spot size of 2 mm. To help facilitate the dissipation of charge
build-up, samples were coated with 5 nm thick layer of Pt prior
to analysis, according to our standard laboratory protocol.12 pSi
MPs were dispersed directly onto conductive aluminium stubs
for analysis, and were not coated for analysis.
Loading and quantification of Infliximab
Infliximab powder was dissolved in 10 mL of sterile MilliQ
water for injection, giving a drug concentration of 10 mg mL1.
The solution was subsequently diluted out in PBS to achieve a
working concentration of 1 mg mL1. The antibody solution
was aliquoted and stored at 80 1C. The loading of Infliximab
(1 mg mL1, pH 7.4) into the oxidised pSi MPs was carried out
using a sealed low protein binding Eppendorf tube. After
loading the MPs were rinsed with PBS (pH 7.4, 15 min) to
remove the weakly adsorbed antibody. The amount of protein
loaded was determined from UV-Vis measurements of the
supernatant before and after incubation with the pSi MPs.
Interferometric reflectance spectroscopy (IRS) of pSi films
IRS was used to monitor the eﬀective optical thickness (EOT)
of the pSi layer in time-lapse mode. The experiments were
performed using an interferometer with a bifurcated fiber on a
motorised stage that allowed the same sample spots to be
accurately analysed. The interferometer consisted of a tungsten
light source and USB2000 CCD Detector (Ocean Optics, USA).
For the EOT comparison, pSi substrates were placed directly on
the motorised stage and monitored in air. For degradation
studies, the pSi substrates were placed in a custom-built cell,
described elsewhere,15 that allowed solutions to be flowed over
the sample while monitoring the EOT in real time.
Infliximab release (using ELISA and L929 assay)
Infliximab loaded pSi-MPs (15 mg) were incubated in 500 mL
PBS, pH 7.2, for 2 or 4 weeks at 25 1C, to more closely mimic
the skin surface temperature, which can vary significantly
especially when wounded.69,70 At days 1, 2, 7, 14, 21 and 28 days,
samples were spun briefly to pellet the pSi and then all of the
supernatant was decanted. A 500 mL aliquot of fresh PBS, pH 7.4,
was added to each sample, to continue the incubation. Each
aliquot was tested for the amount of antibody release via ELISA
(see Section, TNF-a ELISA, below) and TNF-a based bioassay
(see Section, TNF-a cell-based bioassay, below).
Infliximab release (using fluorimetry)
Infliximab (0.1 mg mL1) was labeled with fluorescein isothio-
cyanate (FITC) for 4 h in a sodium carbonate buﬀer (100 mM,
pH 9.5). After labeling the labeled protein was recovered using a
Vivaspin 2 10 000 MWCO spin tube (Sartorius Stedim) according
to the manufacturer’s instructions. This FITC labeled protein
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was then added to unlabeled Infliximab at a ratio of 1 : 5.85 and
this stock was used to load pSi MPs as outlined above. Release
was then monitored on an Agilent Technologies Cary Eclipse
fluorimeter fitted with a Peltier temperature control system
with a PMT of 650 V and excitation and emission slit widths
of 5 nm. The emission was monitored at 525 nm and the
excitation was performed at 490 nm. Data was recorded in an
automated kinetic mode every 8 h for 7 d. The FITC signal was
calibrated against a calibration curve constructed from dilutions
of the FITC labeled Infliximab stock solution.
TNF-a ELISA
The Duo TNF-a ELISA kit (R&D Systems) was used to detect
non-neutralised human TNF-a as per the manufacturer’s
instructions. TNF-a was evaluated in post-pSi supernatant
and TNF-a spiked (1 mg mL1) acute wound fluid (obtained
with institutional ethics approvals Human Research Ethics Com-
mittee, The Queen Elizabeth Hospital, Lyell McEwin Hospital,
Modbury Hospital (TQEH/LMH/MH) Ref#: HREC/12/TQEHLMH/
107). The optical density of each well was determined immedi-
ately using a microplate reader set to 450 nm (Sunriset, Tecan
Group Ltd., Australia).
TNF-a cell-based assay
A cell-based cytotoxic bioassay based on a subclone of the murine
L929 fibroblast cell line (Sigma-Aldrich, Sydney, Australia) was
used.71 Briefly, L929 cells were seeded at 2  104 cells per well in
96-well microtiter plates containing 50 mL of culture medium
(Dulbecco’s modified Eagle’s medium containing 10% (v/v) fetal
bovine serum) (Sigma-Aldrich, Sydney, Australia). The cells were
incubated for 24 h before the addition of 50 mL test solution,
containing from 1 mg mL1 to 1 pg mL1 recombinant human
TNF-a (R&D Systems, Minneapolis, MN), and Infliximab released
from pSi MPs to each well. Fresh Infliximab (1 to 1000 mg mL1)
was added to some wells as a positive control. After a further 24 h
incubation, 20 mL of 2.5 mg mL1 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT; Sigma-Aldrich, Sydney,
Australia) and 50 mL culture medium was added per well and
incubated for 4 h before solubilisation in 100 mL per well 10%
(w/v) sodium dodecyl sulfate-HCl. After a final overnight incuba-
tion, the blue formazan product was measured at 570 nm on a
microplate reader (Sunriset, Tecan Group Ltd., Australia).
Statistical analysis
Statistical diﬀerences were determined using the Student’s
t-test or an ANOVA. For data not following a normal distribu-
tion, the Mann–Whitney U-test was performed. A P value of less
than 0.05 was considered significant.
Results
Infliximab (molecular weight of 149 kDa) has a hydrodynamic
radius of 5–6 nm and an isoelectric point (pI) of approximately
8.3. The radius and the pI dictate that a 410 nm pore radius
and a negative surface charge at neutral pH should be used to
facilitate antibody loading and retention. When working with
monoclonal antibodies, using a buffer with the correct pH and
ionic strength is important.72 As the pI of Infliximab is 8.3
working at pH 7.4 which is below this pI should keep the
Infliximab positively charged and subsequently less likely to
aggregate, hence, helping the protein to remain in its fully
active conformation.73 The original pSi etching conditions were
adapted from previous work by Andrew et al.21 However, we
observed that these conditions resulted in non-homogeneous
pore sizes and a microporous layer formed when etching some
wafers that possess a highly doped surface layer.74 In order to
remove this microporous layer, a sacrificial etching step was
applied (see Fig. S1, ESI†).74 After the sacrificial etching step,
etching current densities from 233 to 150 mA cm2 were used
in combination with etching times from 15 to 240 s. Interfero-
metric reflectance spectroscopy (IRS) analysis of the effective
optical thickness (EOT) from 20 locations on each film showed
that the 233 mA cm2 etch for 20 s produced the most homo-
geneous surfaces with EOT variations of less than 0.20% across
the scanned etched region (see Fig. S2, ESI†).
Scanning electron microscopy (SEM) images of the pSi
surfaces etched using the optimal conditions of 233 mA cm2
for 20 s and oxidised at 400 1C (Fig. 1) revealed pore sizes are
approximately 22.2  4.4 nm. The thickness of the porous layer,
measured via SEM, was 1.39 mm and the porosity, determined
by means of IRS, was 76  5%.
The temperature at which the pSi film surface is oxidised
controls both the extent of antibody loading (assuming that a
larger diﬀerence in net charge between the pSi surface and
antibody encourages more protein binding), and the rate at
which the pSi will degrade in aqueous buﬀers. It is known from
previous work that pSi functionalised at 600 1C or above will not
readily degrade in aqueous solutions either in vitro or in vivo.12
For this reason, we chose to investigate oxidation temperatures
of 300, 400 and 500 1C with freshly etched pSi as a control.
Fig. 2 shows the average degradation curves for each oxidation
temperature over a 2 h period. Combining this analysis with the
pre-determined film thickness, we can estimate the expected
degradation time. As anticipated, the fastest surface to degrade
was the freshly etched pSi surface at a rate of 18.13% EOT per h,
resulting in complete degradation of the film in just 2.5 h
(0.10 d). The time for degradation of the films oxidised at
300 1C extended to 73.8 h (3.1 d at a rate of 0.61% EOT per h).
Fig. 1 Scanning electron microscopy (SEM) images of (A) cross-sectional
view and (B) top down view of the oxidised (400 1C) pSi film.
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This degradation time increased further to 201.3 h (8.4 d at
0.22% EOT per h) for the film oxidised at 400 1C and to 790.0 h
(32.91 d at 0.06% EOT per h) for the sample after 500 1C
oxidation.
The optimal etching conditions were then used to produce
pSi MPs that were thicker in nature than the pSi films (Fig. 3)
and could be suitable for either implantation or injection. pSi
MPs were etched using the conditions adapted from those
optimised for the pSi films, with an etching time of 4 min
and a subsequent 30 s electropolish at 500 mA cm2 to lift oﬀ
the film, which was then subsequently sonicated to generate
particles. SEM revealed that the pSi MPs had a thickness of
23.4  1.3 mm (Fig. 3A). Higher resolution SEM analysis showed
an average pore diameter of 19.5 8.2 nm (Fig. 3B), very similar
to that of the pSi films (22.2  4.4 nm, Fig. 1B). Typical particle
sizes were in the range of 66.5  20.9 mm. Gravimetric analysis
determined the porosity of the pSi MPs to be 84.2  2.0%, again
very close to that of the pSi film preparations (76  5%).
Zeta potential investigations into the pSi MPs prepared with
various oxidation conditions at pH 7.4 revealed that the surface
was negatively charged at about 20 mV for all oxidation
temperatures (Table 1).
This is in line with the literature and is attributed to the
presence of Si–OH on the surface.53 Next, Infliximab binding
was analysed overnight at room temperature by observing the
change in zeta potential of the pSi MPs before and after the
injection of Infliximab at 266 mg mL1 (Fig. 4A).
It was observed that the zeta potential of the MPs after
overnight incubation decreased significantly for all oxidation
conditions, due to the adsorption of protein. Loading of the
Infliximab into the pSi MPs during the zeta measurements was
also confirmed by the UV-Vis spectroscopy of the supernatant
before and after the loading experiment. The supernatant after
loading showed complete removal of the protein peak at
280 nm (Fig. 4B), suggesting that the protein was completely
sequestered by the pSi MPs.
Considering the degradation and zeta potential data, we
chose to use 400 1C oxidised pSi MPs to perform binding
Infliximab experiments since this sample was stable over
several days (the desired timeframe of drug release) and was
negatively charged where Infliximab at pH 7.4 is positively
charged.73
Antibody loading experiments performed at pH 6.5 and 5.5
showed a similar trend in both zeta potential measurements
and UV-Vis analysis (see Fig. S3, ESI†), suggesting no advantage
of loading at more acidic pH values. Subsequently, our typical
loadings of the pSi MPs were performed with approximately
Fig. 2 Degradation profiles over 120 min of freshly etched pSi films as
well as pSi films oxidised at 300 1C, 400 1C and 500 1C, as determined by
IRS measurements in PBS buﬀer at pH 7.2 at 25 1C (n = 3).
Fig. 3 (A) SEMmicrograph showing the size distribution of the pSi MPs and
(B) higher resolution SEM micrograph showing mesopores of the pSi MPs.
Table 1 Zeta potential measurements of pSi MP surfaces oxidised at
diﬀerent temperatures in PBS at pH 7.4 (n = 3)
pSi oxidation temperature (1C) Zeta potential (mV)
300 20.3  0.9
400 19.4  1.5
500 20.3  1.7
Fig. 4 (A) Change in zeta potential upon binding of Infliximab to pSi MPs
in pH 7.4 buﬀer for diﬀerent pSi MP oxidation conditions (300 1C, 400 1C
and 500 1C) (n = 3) and (B) UV-Vis monitoring of the Infliximab in
supernatant during the binding experiment in panel A at pH 7.4.
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15 mg of pSi and 1 mg (at 1 mg mL1) Infliximab in PBS at 7.4.
Loading values were individually assessed by UV-Vis spectro-
photometry of the supernatant before and after for each
particle preparation used, and were typically in the range of
0.063  0.010 mg mg1 similar to literature values.52 Loadings
could be further improved by the use of higher concentrations
of Infliximab (see Table S1, ESI†).
Successful loading of Infliximab was also confirmed by
infrared (IR) spectroscopy. The IR in attenuated total reflection
(ATR) spectra of oxidised pSi (Fig. 5, 400 1C oxidised pSi)
showed a broad, intense peak centered at 1047 cm1 attributed
to the asymmetric stretching of Si–O–Si groups75 and at 887 cm1
due to Si–O bending in O–Si–O.76 The shoulder located at
approximately 1182 cm1 was attributed to the stretching of
surface oxide species including O–Si–O.77–79 After loading of
Infliximab, into the oxidised pSi (Fig. 5, 400 1C oxidised pSi with
Infliximab), the spectra still showed surface peaks characteristic
of oxidised pSi in addition to new peaks at 1465 cm1 from the
asymmetric CH3 deformation and dual peaks at 2850–3000 cm
1
for the C–H stretching vibrations of the protein. Two prominent
peaks at 1542 cm1 and 1639 cm1 were attributed to C–N–H
bending vibrations (amide II) and CQO stretching vibrations
(amide I) of the peptide bonds, respectively.80 The 1247 cm1
peak could also be ascribed to amide III of the protein,81 while the
secondary amine (N–H) stretching appeared at 3290 cm1.80 The
IR results therefore confirm the presence of Infliximab on the pSi
surface. X-ray photoelectron spectroscopy (XPS) further corrobo-
rated those results (Table S2, ESI†).
To verify that Infliximab diﬀused completely through the
oxidised pSi layer, the cross-sections of pSi films before and
after Infliximab loading were imaged by time-of-flight secondary
ion mass spectrometry (ToF-SIMS) to detect characteristic posi-
tive ion fragments, appearing in the mass spectra after loading
Infliximab into pSi. Fig. 6 shows ToF-SIMS images of the total
positive ions and the total intensity of the selected positive
ion fragments C4H10N
+ (m/z 72.081) and C5H12N
+ (m/z 86.096)
characteristic of the amino acids valine and leucine/isoleucine,
respectively82 (see Fig. S4, ESI† for ToF-SIMS mass spectra and
Table S3, ESI† for mass peak assignments). As expected, no
signal was detected for the C4H10N
+ & C5H12N
+ positive fragments
within the oxidised porous layer of the unloaded sample In
contrast, both positive ion fragments were observed after Infliximab
loading. The ToF-SIMS imaging also showed that the protein was
present throughout the porous layer although signal intensity
decreased with increasing depth. It should be noted that in order
to facilitate the ToF-SIMS imaging, a very thick pSi film (80 mm) was
used, much thicker than what was used for pSi MPs (23.4 mm).
Indeed, ToF-SIMS imaging of oxidised pSi MPs after loading with
Infliximab showed representative positive ion fragments, C4H10N
+
(m/z 72.081) and C5H12N
+ (m/z 86.096) over across the MPs (Fig. 7).
As expected, however, mapping these fragments on the unloaded
oxidised pSi MPs showed a very weak intensity. While it was
impractical to cross-section the oxidised pSi MPs, we expected
MPs with open pores on both sides would allow antibody loading
easier than pSi films.
To obtain the antibody release kinetics from the 400 1C pSi
MPs, we followed the emission of FITC-labeled Infliximab
releasing into solution via fluorimetry (Fig. 8A). The release
kinetics appeared initially to show a small burst release
(approx. 5.3% at 8 h) followed by a near linear release profile
(R2 = 0.976) release profile. This is desirable to maximise the
therapeutic benefits of a localised drug delivery platform.83
It was observed that the optimally loaded pSi MPs released the
Infliximab at a rate of 22.56 mg of Infliximab per day. These
results show that the release of Infliximab should continue for
approximately 14 d (47.34% release observed at 7 d).
To test the functionality of the Infliximab released from
the pSi MPs oxidised at 400 1C, we carried out a TNF-a
Fig. 5 ATR-IR spectra of pSi film oxidised at 400 1C before and after
loading of Infliximab.
Fig. 6 ToF-SIMS images (200 mm  200 mm) for the total positive ions
and for the positive ion fragments C4H10N
+ (m/z 72.081) and C5H12N
+ (m/z
86.096) characteristic of the amino acids valine and leucine/isoleucine
acquired on the cross-section of oxidised pSi (400 1C) and infliximab-
loaded oxidised pSi films. Scale bar on the images = 100 mm. To help aid
analysis in imaging mode, pSi films were etched for 20 min to produce a
pSi layer of approximately 80 mm thickness.
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neutralisation ELISA periodically over 14 d. Infliximab released
from pSi was functional with 490% TNF-a neutralisation
observed for the day 1 and 2 samples (Fig. 8B, black bars).
However, the activity of the released Infliximab diminished
over time, with no eﬀect observed past the day 7 time-point.
Infliximab functionality when incubated in the absence of pSi
(Fig. 8B, grey bars) (at an equivalent concentration to the
amount released from pSi) was less than observed for anti-
body released from pSi, with no activity detected after the
2 day time-point. This indicated that the incubation of low
concentrations of Infliximab in PBS at 25 1C leads to degrada-
tion, providing a limitation for the assay, but importantly
provided evidence that pSi protected Infliximab from degra-
dation prior to release.
To confirm that Infliximab released from pSi MPs neutra-
lises TNF-a, whilst showing eﬃcacy in a cellular environment, a
L929 cell bioassay was used.71,84 Recovery of TNF-a treated L929
cells was assessed after 7, 14, 21 and 28 d of release. Recombi-
nant TNF-a was cytotoxic to L929 cells in a dose dependent
manner ( p o 0.005) (Fig. S5, ESI†) and this cytotoxicity could
subsequently be inhibited by Infliximab at Z5 mg mL1
(Fig. S6, ESI†). The addition of supernatant from Infliximab-
loaded pSi MPs was demonstrated to increase L929 cell viability
for up to 21 d (Fig. 9A). It should be noted that the MTT assay
(Fig. 9A) showed the presence of functional Infliximab in
samples up to day 28, longer than could be detected by ELISA
(Fig. 8B). The discrepancy may be caused by diﬀerences in the
sensitivity of these two assays and variations in the strength
of TNF-a–Infliximab binding due to the different buffers, pH
values and incubation times required. Together, the ELISA and
L929 cell bioassay was able to confirm that Infliximab released
from pSi MPs remained both stable and active.
The applicability of this system with conditions closer to
a wound environment was demonstrated via the neutralisa-
tion of TNF-a spiked into acute wound fluid (AWF) from 3
diﬀerent patients (Fig. 9B). Time points of 1, 2, 7 and 14 d
were analysed with the L929 cell bioassay. L929 cells could
recover 425% when exposed to supernatant incubated for
1 and 2 d. This result suggests that the pSi MPs loaded with
Infliximab were able to neutralise the TNF-a in actual wound
fluid samples. Additionally, the range of conditions in which
Infliximab remained active was tested via the L929 assay.
We observed that the L929 cells were able to respond to
Infliximab treatment when high concentrations (1 mg mL1)
of Infliximab were held at pH values ranging from 4.5–8.5
and temperatures ranging from 4 1C to 37 1C for up to 7 d
(see Fig. S7, ESI†). It was observed that even at the extreme
pH values and temperatures approximately 70% cell recovery
was observed.
The data presented here demonstrates that Infliximab is able
to bind to TNF-a in a wound environment and subsequently
reduces its activity. These results suggest the wide range and
Fig. 7 ToF-SIMS images (200 mm 200 mm) for the total positive ions and
for the positive ion fragments C4H10N
+ (m/z 72.081) and C5H12N
+ (m/z
86.096) characteristic of the amino acids valine and leucine/isoleucine
acquired on the oxidized pSi (400 1C) and infliximab-loaded pSi MPs. Scale
bar on the images = 100 mm.
Fig. 8 (A) FITC tracking of Infliximab released at 25 1C pH 7.4 from
oxidised pSi MPs (400 1C) over a 7 day period. (B) ELISA detection of
TNF-a. Supernatant containing Infliximab released from pSi was incubated
with human TNF-a for 10 minutes at 37 1C. Non-neutralised TNF-a was
then detected by ELISA. Supernatant was collected from 400 1C oxidised
pSi MPs loaded with Infliximab and incubated at 25 1C over a 14 day period
(black bars). Fresh Infliximab (i.e. not associated with pSi MPs) was also
incubated in PBS (gray bars). Data at each time point are presented as the %
inhibition of TNF-a by Infliximab. The assay was performed in triplicate and
presented as mean  one standard deviation.
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applicability of the delivery of Infliximab for applications ranging
from wound healing to uveitis.
Conclusions
We demonstrate that oxidised pSi films and MPs have a high
loading capacity for Infliximab and extend antibody release
in vitro. In particular, we show near linear release kinetics of
Infliximab from oxidized pSi MPs over 8 days. The released
Infliximab was able to prevent apoptosis of L929 cells in acute
wound fluid by sequestering TNF-a over 7 days, a period
suitable for a clinical application. Hence, with optimised tuning
of the porous structure and its surface, the pSi films and MPs
described here may represent a form of resorbable and bio-
compatible therapeutic carrier for extended drug delivery requiring
no surgical removal. It is envisaged that pSi MPs can be incorpo-
rated into wound dressings materials and deliver Infliximab to
wound fluid in order to improve chronic wound healing. We also
believe that the same Infliximab-releasing pSi MP format may be fit
for the purpose of treating uveitis.
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